143 related articles for article (PubMed ID: 22722460)
1. Epithelioid hemangioendothelioma of the kidney treated with sunitinib.
Tolkach Y; Petrov S; Lerut E; Van Poppel H
Onkologie; 2012; 35(6):376-8. PubMed ID: 22722460
[TBL] [Abstract][Full Text] [Related]
2. Metastatic hepatic epithelioid hemangio-endothelioma: long-term response to sunitinib malate.
Saada E; Saint Paul MC; Gugenheim J; Follana P; François E
Oncol Res Treat; 2014; 37(3):124-6. PubMed ID: 24685916
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
Semenisty V; Naroditsky I; Keidar Z; Bar-Sela G
BMC Cancer; 2015 May; 15():402. PubMed ID: 25967676
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
Mascarenhas RC; Sanghvi AN; Friedlander L; Geyer SJ; Beasley HS; Van Thiel DH
Oncology; 2004; 67(5-6):471-5. PubMed ID: 15714004
[TBL] [Abstract][Full Text] [Related]
5. Primary epithelioid hemangioendothelioma of the kidney: the first case report in a child and literature review.
Xiao Y; Wang C; Song Y; Wang C; Wang X; Zhang X; Xu A
Urology; 2013 Oct; 82(4):925-7. PubMed ID: 23726166
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant sunitinib facilitates nephron-sparing surgery and avoids long-term dialysis in a patient with metachronous contralateral renal cell carcinoma.
Ansari J; Doherty A; McCafferty I; Wallace M; Deshmukh N; Porfiri E
Clin Genitourin Cancer; 2009 Aug; 7(2):E39-41. PubMed ID: 19692322
[TBL] [Abstract][Full Text] [Related]
8. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
9. Long-term response with sunitinib for metastatic renal cell carcinoma.
Ronnen EA; Kondagunta GV; Ginsberg MS; Russo P; Motzer RJ
Urology; 2006 Sep; 68(3):672.e19-20. PubMed ID: 16979716
[TBL] [Abstract][Full Text] [Related]
10. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
11. Malignant epithelioid hemangioendothelioma of the bladder: the first case report in a child.
Geramizadeh B; Banani A; Foroutan H; Aminsharifi A; Karimi M
J Pediatr Surg; 2009 Jul; 44(7):1443-5. PubMed ID: 19573676
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: a new predictive factor?
Gambini D; Locatelli E; Gianelli U; Bareggi C; Galassi B; Visintin R; Massironi S; Dell'orto PG; Tomirotti M
Anticancer Res; 2014 Dec; 34(12):7361-5. PubMed ID: 25503173
[TBL] [Abstract][Full Text] [Related]
13. Beyond the maths of biology: long-term spontaneous tumoral regression after sunitinib withdrawal.
Teo M; Downey FP; McDermott RS
Clin Genitourin Cancer; 2013 Jun; 11(2):198-200. PubMed ID: 23276590
[No Abstract] [Full Text] [Related]
14. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib for metastatic renal cell carcinoma.
Mukherji D; Larkin J; Pickering L
Future Oncol; 2010 Sep; 6(9):1377-85. PubMed ID: 20919823
[TBL] [Abstract][Full Text] [Related]
16. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma.
Lane BR; Derweesh IH; Kim HL; O'Malley R; Klink J; Ercole CE; Palazzi KL; Thomas AA; Rini BI; Campbell SC
Urol Oncol; 2015 Mar; 33(3):112.e15-21. PubMed ID: 25532471
[TBL] [Abstract][Full Text] [Related]
17. Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment.
Rosenberg A; Agulnik M
Curr Treat Options Oncol; 2018 Mar; 19(4):19. PubMed ID: 29546487
[TBL] [Abstract][Full Text] [Related]
18. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
[TBL] [Abstract][Full Text] [Related]
19. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
20. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
